Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,857 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subcutaneous injection Clear all
Completed Phase 3 Interventional Results available

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

NCT00577863
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Huntsville, Alabama • Montgomery, Alabama • Peoria, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 15, 2026, 11:33 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05681481
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
efgartigimod PH20 SC, Prednisone
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Active, not recruiting Phase 2 Interventional

Vosoritide for Selected Genetic Causes of Short Stature

NCT04219007
View directory record Official record
Conditions
Short Stature
Interventions
Vosoritide
Drug
Lead sponsor
Andrew Dauber
Other
Eligibility
3 Years to 10 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A

NCT02994407
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Orlando, Florida • Iowa City, Iowa • East Lansing, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of Stellate Ganglion Injection to Provide Relief From Hot Flushes

NCT00992914
View directory record Official record
Conditions
Hot Flashes, Menopause
Interventions
Sympathetic nerve block with 1% lidocaine 1-2 ml, Superficial subcutaneous injection
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)

NCT01212744
View directory record Official record
Conditions
Phenylketonuria
Interventions
rAvPAL-PEG
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
16 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Aurora, Colorado • Gainesville, Florida • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of TAK-004 in Healthy Adults

NCT06236009
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-004, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

NCT06388187
View directory record Official record
Conditions
Obesity
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Costa Mesa, California • Plantation, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

NCT02724228
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
7 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Oakland, California • Torrance, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Active, not recruiting Phase 2 Interventional

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

NCT07446998
View directory record Official record
Conditions
Obesity & Overweight, Mobility Disability, HOMA-IR
Interventions
Enobosarm, Semaglutide (Wegovy) weekly injection
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
65 Years to 100 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Doral, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Recruiting Phase 2 Interventional

Lerapolturev (PVSRIPO) in GBM

NCT06177964
View directory record Official record
Conditions
Recurrent Supratentorial Glioblastoma
Interventions
Lerapolturev, Lomustine Pill
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

NCT05216887
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Aducanumab
Biological
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 70 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 15, 2026, 11:33 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT04045028
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
Interventions
Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

Feasibility Trial Testing the Bionic Pancreas With ZP4207

NCT02971228
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
Drug · Device
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 15, 2026, 11:33 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

NCT06488209
View directory record Official record
Conditions
Healthy Volunteers, Autoimmune Disease
Interventions
LAD191, Placebo
Drug · Other
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Miami, Florida • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 15, 2026, 11:33 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

NCT03410056
View directory record Official record
Conditions
Rheumatoid Arthritis RA
Interventions
Efavaleukin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
Anniston, Alabama • Torrance, California • Lansing, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

NCT04250337
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, Topical Corticosteroid
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
43
States / cities
Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

NCT01169103
View directory record Official record
Conditions
Obesity
Interventions
recombinant human growth hormone (rhGH), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 3 Interventional Results available

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

NCT00566722
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 1 Interventional

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

NCT04554966
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
ABBV-382, Placebo for ABBV-382
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Albiglutide in Type 2 Diabetes

NCT00849056
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
310
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 250 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 15, 2026, 11:33 AM EDT
Recruiting Phase 1 Interventional

GTB-5550 in Advanced Solid Tumors

NCT07541573
View directory record Official record
Conditions
Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
Interventions
GTB-5550
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 15, 2026, 11:33 AM EDT